Clinical Trial Readiness for the Dystroglycanopathies

$362,119U54FY2013NSNIH

University Of Iowa, Iowa City IA

Investigators

Linked publications & trials

Paper 38732148 Paper 37873263 Paper 37247532 Paper 36723429 Paper 36399172 Paper 35750689 Paper 35597713 Paper 35165973 Paper 34884219 Paper 34857438 Paper 34787322 Paper 34737451 Paper 34568901 Paper 34384893 Paper 33755597 Paper 33501999 Paper 33449170 Paper 33443126 Paper 33415332 Paper 33074106 Paper 32914449 Paper 32827036 Paper 32764098 Paper 32754643 Paper 32620803 Paper 32529201 Paper 32149355 Paper 32115343 Paper 32042916 Paper 31844279 Paper 31463572 Paper 31427525 Paper 31299614 Paper 31243061 Paper 31097590 Paper 31054580 Paper 31041397 Paper 30987788 Paper 30932294 Paper 30914516 Paper 30911578 Paper 30854202 Paper 30827497 Paper 30656193 Paper 30636004 Paper 30588381 Paper 30239736 Paper 30168727 Paper 30153853 Paper 29980640 Paper 29882456 Paper 29855340 Paper 29779439 Paper 29759639 Paper 29685414 Paper 29665321 Paper 29365344 Paper 29101272 Paper 28974147 Paper 28881388 Paper 28760865 Paper 28697784 Paper 28533353 Paper 28416349 Paper 28087826 Paper 28067909 Paper 27879205 Paper 27872178 Paper 27821570 Paper 27773428 Paper 27707967 Paper 27625424 Paper 27526028 Paper 27496765 Paper 27130732 Paper 27099343 Paper 26948708 Paper 26908621 Paper 26829621 Paper 26823526 Paper 26464793 Paper 26310427 Paper 26255073 Paper 26227883 Paper 26109717 Paper 26100331 Paper 25996830 Paper 25921929 Paper 25882296 Paper 25878907 Paper 25802879 Paper 25770200 Paper 25568299 Paper 25537791 Paper 25279699 Paper 25138275 Paper 25042182 Paper 24778262 Paper 24581957 Paper 24491487

Abstract

The purpose of this project is to gather the information and create the infrastructure needed to plan and carry out clinical trials for patients with deficient glycosylation of alpha-dystroglycan. These patients have muscular dystrophy, with or without multisystem involvement (the dystroglycanopathies). Thus far, mutations in six genes (POMT1, P0MT2, POMGnT1, FKTN, FKRP, and LARGE) are known to result in dystroglycanopathies. There are several clinical subtypes, and these have overlapping phenotypes. The dystroglycanopathy population poses special challenges in thinking about treatment trials due to the wide range in clinical severity. In addition, the cognitive impairment seen in some of the subtypes limits patients' ability to cooperate with testing. In Aim 1, we will recruit patients with suspected or proven dystroglycanopathies and define their clinical phenotypes using historical information, standardized functional tests, and muscle ultrasound. In cooperation with Core B, we will evaluate muscle biopsies, define patients' alpha-dystroglycan glycosylation status in cultured fibroblasts, and determine their genotype. In Aim 2, we will follow patients with dystroglycanopathy longitudinally using a battery of potential clinical trial outcome measures. This will provide us with natural history information and determine optimal outcome measures for use in therapeutic trials. In Aim 3, we will develop the infrastructure for a proposed clinical trial of corticosteroids, using the data collected in Aims 1 and 2 to guide trial design. Anecdotes and case reports suggest corticosteroids are beneficial in patients with the dystroglycanopathies. In this proposal, we will develop the patient cohort, outcome markers and infrastructure to test this hypothesis. We expect that the results of these three aims will prepare us to evaluate novel treatments for these rare forms of muscular dystrophy as they become available.

View original record on NIH RePORTER →